<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083119</url>
  </required_header>
  <id_info>
    <org_study_id>81473561</org_study_id>
    <nct_id>NCT03083119</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina</brief_title>
  <official_title>The Methylation Regulation Mechanism of Blood Stasis Relevant miRNA Expression on Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jie Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, typical cases of coronary heart disease are selected. They will be intervened
      by Xuesaitong soft capsules to investigate efficacy and safety for Coronary Heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2017</start_date>
  <completion_date type="Anticipated">August 20, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major adverse cardiovascular events</measure>
    <time_frame>60 days</time_frame>
    <description>death, myocardial infarction, hospitalization for unstable angina or stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seattle Angina Questionnaire</measure>
    <time_frame>60 days</time_frame>
    <description>to evaluate patients by Seattle Angina Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood stasis syndrome scale of Coronary heart disease angina pectoris</measure>
    <time_frame>60</time_frame>
    <description>to evaluate patients by blood stasis syndrome scale of Coronary heart disease angina pectoris</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lipid</measure>
    <time_frame>60</time_frame>
    <description>Triacylglyceride,total cholesterol, low densith lipoprotein, high densith lipoprotein</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Xuesaitong soft capsule group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xuesaitong soft capsule</intervention_name>
    <description>Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.</description>
    <arm_group_label>Xuesaitong soft capsule group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of coronary angiography unstable angina

          -  Clinical diagnosis of unstable angina

          -  Age of 30 to 75 years old

          -  Not use thrombolysis, dilate coronary drugs within two weeks

          -  Sign the consent

        Exclusion Criteria:

          -  Severe valvular heart disease

          -  Insulin-dependent diabetes

          -  mental disease

          -  Combined with severe liver, kidney, hematopoietic system disorder

          -  Patients with malignant tumors

          -  Pregnancy or breast-feeding women

          -  Recent history of trauma

          -  Drug allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang Anmen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lian Duan</last_name>
    <phone>+8601088001817</phone>
    <email>popale2003@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guang Anmen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lian Duan</last_name>
      <phone>+8601088001817</phone>
      <email>popale2003@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jie Wang</investigator_full_name>
    <investigator_title>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

